Naomi Galili

Summary

Affiliation: St. Vincent's Comprehensive Cancer Center
Country: USA

Publications

  1. ncbi Isolation of specific and biologically active peptides that bind cells from patients with acute myeloid leukemia (AML)
    Naomi Galili
    Saint Vincent s Comprehensive Cancer Center, New York, NY, USA
    J Hematol Oncol 1:8. 2008
  2. ncbi Clinical implications of gene expression profiling in myelodysplastic syndromes: recognition of ribosomal and translational gene dysregulation and development of predictive assays
    Naomi Galili
    St Vincent s Comprehensive Cancer Center, 325 West 15th Street, New York, NY 10011, USA
    Best Pract Res Clin Haematol 22:223-37. 2009
  3. ncbi Oral Ezatiostat HCl (TLK199) and Myelodysplastic syndrome: a case report of sustained hematologic response following an abbreviated exposure
    Fahd Quddus
    Dept of Hematology and Oncology, University of Nebraska Medical Center, Omaha, NE 68198, USA
    J Hematol Oncol 3:16. 2010
  4. ncbi Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome
    Azra Raza
    University of Massachusetts Medical Center, Worcester, MA, USA
    J Hematol Oncol 2:20. 2009
  5. ncbi Pharmacotherapy of myelodysplastic syndromes
    Naomi Galili
    St Vincent s Comprehensive Cancer Center, 325 West 15th Street, New York 10011, USA
    Expert Opin Pharmacother 11:1889-99. 2010
  6. ncbi Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia
    Azra Raza
    Department of Medicine, St Vincent s Comprehensive Cancer Center, New York, New York 10011, USA
    Cancer 113:1596-604. 2008
  7. ncbi Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial
    Azra Raza
    St Vincent s Comprehensive Cancer Center, New York, NY, USA
    Leuk Lymphoma 50:1336-44. 2009
  8. ncbi Prognosis in myelodysplastic syndromes: are the new classifications useful?
    Naomi Galili
    St Vincent s Comprehensive Cancer Center, New York, NY 10011, USA
    Curr Hematol Malig Rep 3:19-22. 2008
  9. ncbi A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome
    Azra Raza
    Columbia University Medical Center, Milstein Hospital Bldg, 6N 435, 177 Fort Washington Avenue, New York, NY 10032, USA
    Cancer 118:2138-47. 2012
  10. ncbi MDS: Refining existing therapy through improved biologic insights
    Jordan Schecter
    The MDS Center at Columbia University, New York, NY, USA
    Blood Rev 26:73-80. 2012

Detail Information

Publications10

  1. ncbi Isolation of specific and biologically active peptides that bind cells from patients with acute myeloid leukemia (AML)
    Naomi Galili
    Saint Vincent s Comprehensive Cancer Center, New York, NY, USA
    J Hematol Oncol 1:8. 2008
    ....
  2. ncbi Clinical implications of gene expression profiling in myelodysplastic syndromes: recognition of ribosomal and translational gene dysregulation and development of predictive assays
    Naomi Galili
    St Vincent s Comprehensive Cancer Center, 325 West 15th Street, New York, NY 10011, USA
    Best Pract Res Clin Haematol 22:223-37. 2009
    ..These biologic and clinical insights are providing the framework on which to build a new model of these diseases which, despite their heterogeneity, manifest certain unifying themes...
  3. ncbi Oral Ezatiostat HCl (TLK199) and Myelodysplastic syndrome: a case report of sustained hematologic response following an abbreviated exposure
    Fahd Quddus
    Dept of Hematology and Oncology, University of Nebraska Medical Center, Omaha, NE 68198, USA
    J Hematol Oncol 3:16. 2010
    ....
  4. ncbi Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome
    Azra Raza
    University of Massachusetts Medical Center, Worcester, MA, USA
    J Hematol Oncol 2:20. 2009
    ..In phase 2, ezatiostat was administered on 2 dose schedules: 600 mg/m2 IV on days 1 to 5 or days 1 to 3 of a 21-day treatment cycle...
  5. ncbi Pharmacotherapy of myelodysplastic syndromes
    Naomi Galili
    St Vincent s Comprehensive Cancer Center, 325 West 15th Street, New York 10011, USA
    Expert Opin Pharmacother 11:1889-99. 2010
    ..While there is no single answer to these issues, there are several approaches that may be considered, and these are addressed in this review...
  6. ncbi Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia
    Azra Raza
    Department of Medicine, St Vincent s Comprehensive Cancer Center, New York, New York 10011, USA
    Cancer 113:1596-604. 2008
    ..Eventually, 30% of patients with MDS will progress and develop acute myeloid leukemia (AML). New strategies are needed for these patients...
  7. ncbi Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial
    Azra Raza
    St Vincent s Comprehensive Cancer Center, New York, NY, USA
    Leuk Lymphoma 50:1336-44. 2009
    ..In contrast to aggressive conventional chemotherapy, lintuzumab was administered in an ambulatory clinic setting with acceptable toxicity...
  8. ncbi Prognosis in myelodysplastic syndromes: are the new classifications useful?
    Naomi Galili
    St Vincent s Comprehensive Cancer Center, New York, NY 10011, USA
    Curr Hematol Malig Rep 3:19-22. 2008
    ..Clinical symptoms and degree of transfusion dependency will dictate the degree of therapeutic intervention...
  9. ncbi A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome
    Azra Raza
    Columbia University Medical Center, Milstein Hospital Bldg, 6N 435, 177 Fort Washington Avenue, New York, NY 10032, USA
    Cancer 118:2138-47. 2012
    ..This study evaluated 2 extended dose schedules of oral ezatiostat in 89 heavily pretreated patients with low to intermediate-1 risk myelodysplastic syndrome (MDS)...
  10. ncbi MDS: Refining existing therapy through improved biologic insights
    Jordan Schecter
    The MDS Center at Columbia University, New York, NY, USA
    Blood Rev 26:73-80. 2012
    ..We expect that through advancing biologic insights, the use of such therapies will become more selective and refined...